POINT Biopharma Global Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PNT research report →
Companywww.pointbiopharma.com
POINT Biopharma Global Inc. , a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
- CEO
- Joe A. McCann
- IPO
- 2020
- Employees
- 129
- HQ
- Indianapolis, IN, US
Price Chart
Valuation
- Market Cap
- $1.33B
- P/E
- 12.03
- P/S
- 5.88
- P/B
- 2.43
- EV/EBITDA
- 8.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 55.40%
- Net Margin
- 43.38%
- ROE
- 26.49%
- ROIC
- 19.10%
Growth & Income
- Revenue
- $226.58M · 0.00%
- Net Income
- $98.29M · 314.13%
- EPS
- $1.04 · 267.74%
- Op Income
- $125.52M
- FCF YoY
- 419.16%
Performance & Tape
- 52W High
- $14.35
- 52W Low
- $6.57
- 50D MA
- $13.22
- 200D MA
- $9.77
- Beta
- -0.00
- Avg Volume
- 3.85M
Get TickerSpark's AI analysis on PNT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 44,749 |
| Dec 26, 23 | GOODMAN JONATHAN R. | other | 41,872 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 35,872 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 25,000 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 25,614 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 26,904 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 4,932 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 77,958 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 98,358 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 70,000 |
Our PNT Coverage
We haven't published any research on PNT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PNT Report →